Background: The current treatment of choice for symptomatic aortic stenosis is aortic valve replacement (AVR) with cardiopulmonary bypass (CPB), but AVR is associated with significant operative morbidity and mortality in elderly patients with multiple co-morbid conditions. We recently reported the first successful aortic valve implantation procedure (AVI) via a mini-thoracotomy and left ventricular apical puncture without cardiopulmonary bypass. We now report 6-month follow-up in our initial seven patients. Methods: Seven patients (77 AE 10 years old) with symptomatic aortic stenosis were deemed to be non-surgical candidates for AVR and not suitable for a transfemoral percutaneous heart valve implantation due to aorto-iliac disease. The predicted 30-day operative mortality was 31 AE 23% according to logistic Euroscore. Patients underwent minimally invasive transapical AVI. With the guidance of fluoroscopy and transesophageal echocardiography, balloon predilation was followed by deployment of a 26 mm Cribier-Edwards TM valve (Edwards Lifesciences Inc., Irvine, CA) during rapid ventricular pacing to reduce forward flow and cardiac motion. Results: Valve implantation was successful in all seven patients. There were no intra-procedural mortalities or complications. Thirty-day operative mortality was 14%. One patient died at day 12 due to pneumonia. Two patients died from non-cardiac diseases at day 51 and 85. The remaining four patients completed 6-month follow-up. The aortic valve area increased from 0.7 AE 0.3 to 1.8 AE 0.7 and 1.5 AE 0.5 cm 2 at 1 and 6 months, respectively. The mean transaortic gradient was reduced from 32 AE 8 to 10 AE 5 and 11 AE 8 mmHg at 1 and 6 months, respectively. Following AVI, none or trivial, mild, and moderate aortic regurgitation was observed in 4, 2, and 1 patients, respectively. There were no valve-related complications during the follow-up. Conclusion: Aortic valve implantation can successfully be performed via a minimally invasive apical approach without the need for cardiopulmonary bypass. The early results in this initial series are encouraging. This initial experience suggests that the minimally invasive transapical approach is a viable alternative for patients in whom open-heart surgery is not feasible or poses unacceptable risks. #
Introduction
Aortic valve replacement (AVR) with cardiopulmonary bypass (CPB) has been the only treatment modality that offers both symptomatic relief and the potential for improved long-term survival, and hence is the treatment of choice for patients with symptomatic severe degenerative aortic stenosis [1] . Symptomatic patients managed medically have a poor prognosis [2] [3] [4] and the hope of durable benefit with balloon aortic valvuloplasty has not been realized [4] [5] [6] . However, since many patients with symptomatic severe aortic stenosis have significant co-morbidities, open heart AVR with CPB can be associated with an unacceptable perioperative mortality and morbidity.
Several groups have pursued the development of transcatheter valves [7] [8] [9] [10] [11] [12] [13] . Percutaneous aortic valve implantation (AVI) in humans was first performed as a femoral transvenous procedure with antegrade access to the aortic valve [14] [15] [16] . Subsequently, Webb and co-workers [17, 18] reported a femoral transarterial procedure. Our group's initial animal developmental work utilized direct balloon catheter implantation of an aortic valve through the left ventricular apex [12] . Recently, we reported the first successful case in which the transarterial delivery system was utilized to implant an aortic valve via the apex of the left ventricle without CPB in human [19, 20] . Subsequently, we have reported our 1-month follow-up data in seven patients who underwent transapical transcatheter aortic valve implantation [21] . We have now completed 6-month clinical and echocardiographic follow-up in this cohort of patients who underwent transapical aortic valve implantation via a left mini-thoracotomy without CPB.
Methods
The procedure was approved by the Therapeutic Products Directorate, Department of Health and Welfare, Ottawa, Canada, for compassionate clinical use in patients deemed not to be candidates for routine surgery and unsuitable for percutaneous trans-femoral arterial valve implantation.
Patients
All patients had symptomatic severe aortic stenosis and were judged to be at unacceptably high risk for routine openheart AVR with CPB because of significant co-morbidity. Mortality risk as estimated by logistic Euroscore [22] was 31 AE 23%. Patients were initially assessed for percutaneous transfemoral arterial valve implantation but were unsuitable due to atherosclerosis or unfavorable anatomy in the aorta and/or ilio-femoral arteries. The clinical characteristics of our initial seven patients are shown in Table 1 . The Euroscore of each patient is listed in Table 1 . Three patients (Patients 2, 4, and 5) had low Euroscore, however, they were not accepted for conventional AVR because in patient 2 conventional AVR was abandoned due to porceline aorta, patient 4 had multiple stroke with dementia, and patients 5 had end-stage lung disease.
Prosthetic valve system
The Cribier-Edwards TM valve (Edwards Lifesciences Inc., Irvine, CA) is constructed from a tubular slotted stainless steel stent with an attached equine pericardial trileaflet valve (Fig. 1) . A sewn fabric cuff covers the left ventricular portion of the prosthesis. In-vitro durability of the prosthetic valve has been repeatedly demonstrated to be in excess of 200 million cardiac cycles, corresponding to over 5 years of life. Valves are supplied sterile in glutaraldehyde. Currently, only 23 and 26 mm external diameter prostheses are available for transapical use. Based on our percutaneous experience, the 26 mm prosthesis was considered appropriate for an echocardiographic annulus diameter of 20-25 mm.
A mechanical crimping device is utilized to attach the prosthesis onto a specially constructed balloon deployment catheter. In these initial apical access cases, we utilized the catheter delivery system designed for percutaneous femoral arterial access [17] . For the transapical approach, the occlusive fabric skirt must be mounted proximally on the balloon catheter. In this system, the balloon delivery catheter shaft is contained within a steerable guiding catheter that can be actively flexed by rotation of an external handle.
Procedure
Patients were premedicated with aspirin, clopidogrel, and vancomycin. Procedures were performed by a team of cardiac surgeons and cardiologists in an operating room equipped with fluoroscopy. General anesthesia was utilized. Double lumen intubation was found to be unnecessary because lung deflation was not required during the procedure. We now use single lumen intubation in all cases. The apex of the left ventricle was identified by palpation and fluoroscopy. The pleural space overlying the apex (the fifth or sixth intercostal space) was entered via an approximately 5 cm anterolateral mini-thoracotomy. The pericardium over the apex of the left ventricle was identified and opened. Temporary epicardial ventricular pacing wires were placed on the left ventricle. Reliable capture was assured at a rate of between 160 and 220 beats per minute with a reduction in systemic systolic arterial pressure to below 60 mmHg. During valvuloplasty and prosthesis deployment, rapid pacing was utilized to minimize transaortic flow and cardiac motion [19, 21] . The thin portion of the left ventricular apex was identified by finger palpation and confirmed by simultaneous transesophageal echocardiographic imaging (TEE). Two paired orthogonal U-shaped sutures with pledgets were placed into the myocardium and passed through tensioning tourniquets. Heparin was administered to achieve an activated clotting time of >250 s. An arterial needle puncture allowed placement of a 7 French sheath through the apex into the left ventricular cavity utilizing a standard over the wire technique. A wire (0.035 in. J-curve Amplatz extra stiff TM , Cook Inc.) was advanced through the aortic valve, around the arch and into the descending aorta for stability. If necessary a balloon catheter (Berman TM , Cook Inc.) was utilized to direct the wire in the direction of arterial flow past mitral chordae and around the aortic arch (rarely required). The 7F sheath was then exchanged for a 14 French sheath. A valvuloplasty balloon (20-22 mm, Z-Med TM , Numed Inc., Hopkington, NY) was advanced over the wire to the level of the ascending aorta, evacuated of air and test inflated with diluted contrast. The balloon was withdrawn to the level of the valve as determined by fluoroscopy and TEE. Rapid pacing was initiated and when an adequate reduction in systemic arterial pressure was achieved the balloon was rapidly inflated and deflated [19, 21] . The 14 French sheath was exchanged over the wire for a 24 French sheath for valve delivery. The prosthetic valve mounted on a delivery balloon supported by a steerable catheter was introduced through the sheath over the Amplatzer wire. The prosthetic valve was advanced to the aortic valve and placed at the level of fluoroscopically visible valvular calcium. Aortic root angiography via a pigtail catheter introduced from the femoral artery and TEE were used to further aid positioning. When an adequate reduction in systemic arterial pressure was achieved with rapid pacing, the prosthetic valve was deployed using a rapid manual inflation/deflation of the delivery balloon (Fig. 2) . Following deployment, valve function was assessed by TEE (Fig. 3) and angiography. In two of the seven patients, paravalvular insufficiency was excessive and dilatation of the prosthesis was repeated. After removal of the left ventricular sheath, hemostasis was secured with the previously placed pledgeted sutures. The pericardium was approximated to prevent myocardial herniation but allow drainage. A left chest tube was placed [19, 21] . Patients were maintained on aspirin indefinitely and clopidogrel for at least 1 month. Transthoracic echocardiography was performed prior to discharge or transfer to another hospital. The authors did not observe any obstruction of coronary ostia in this cohort of patients after the deployment of the tissue valve.
Follow-up
All patients have been carefully followed by both cardiac surgeons and cardiologists. Clinical assessment was performed by either the patients' cardiologists or cardiac surgeons. Follow-up echocardiography was performed at 1 and 6 months. We have completed 6-month follow-up in this initial cohort of seven patients who underwent minimally invasive transapical aortic valve implantation.
Statistical analysis
Normally distributed data were reported as mean AE stanstandard deviation. Non-parametric data were reported as median (inter quartile range). No statistical analysis was performed due to limited sample size in this series.
Results

Intraoperative results
Transapical aortic valve implantation via a left minithoracotomy without CPB was successfully performed in all seven patients with severe symptomatic aortic stenosis. All patients received 26 mm diameter prostheses. Paravalvular regurgitation was moderate by TEE in two patients in whom redilation resulted in further expansion of the prosthesis and a satisfactory reduction in paravalvular regurgitation. At the completion of the procedure, aortic insufficiency grade was 1 (1,2) by TTE. There was no obstruction of coronary ostia in this cohort of patients and no intraoperative complications or mortality. We did not experience any hemostatic problems in closing the puncture site of the left ventricular apex. All patients tolerated the procedure very well. Procedural characteristics are shown in Table 2 .
Clinical follow-up
Of the first seven patients, five patients were discharged home and one transferred to another hospital for convalescent care. The 7th patient, who had a predicted surgical mortality of 58% based on the logistic Euroscore, died at day 12 due to pneumonia. The median hospital stay prior to discharge or transfer was 8 (6, 14) days. The delayed hospital discharge was mainly due to preoperatively comorbidities. There were no significant postoperative complications, except pleural effusion requiring tube drainage in one patient, and lower urinary tract infection in another patient. At 1-and 6-month follow-up, preoperative symptoms related to severe aortic stenosis were either resolved or significantly improved. Postoperative NYHA class remained unchanged in only one patient who had end-stage lung disease that existed preoperatively. This patient died from his end-stage lung disease at postoperative day 51. Another patient died from cancer at day 85. The other four patients continue to do well with significantly improved quality of life.
Echocardiographic follow-up
Echocardiography was performed prior to hospital discharge (seven patients), and at 1 month (six patients) and 6 month (four patients). Echocardiography performed prior to hospital discharge demonstrated (1) well-seated aortic valves with normal valve function in all seven patients, (2) moderate paravalvular regurgitation in one patient, mild paravalvular regurgitation in two patients, and non or trivial paravalvular regurgitation in four patients, (3) aortic valve area of 1.6 AE 0.6 cm 2 , and (4) mean transaortic gradient of 10 AE 7 mmHg. These measurements were maintained at 1-and 6-month follow-up (Table 3 ). In no patient did paravalvular insufficiency appear clinically significant. Decreases in mitral regurgitation were observed at 1-and 6-month echocardiographic follow-up (Table 3) . LV function shows an improving trend at 6-month follow-up (Table 3 ).
Discussion
Aortic valve replacement is the treatment of choice in patients with severe symptomatic acquired aortic stenosis, offering both symptomatic relief and the potential of improved long-term survival [1] . Symptomatic patients managed medically have a poor prognosis [2] [3] [4] . Balloon valvuloplasty is palliative and although it may result in temporary relief of symptoms, benefit is modest and restenosis certain [6, 23] .
Unfortunately, many potential surgical candidates have significant co-morbid conditions and open-heart surgery with CPB may pose risks that are unacceptable to them or their physicians. According to the Society of Thoracic Surgery Database (1998-2001) surgical aortic valve replacement carries a rate of serious complication or mortality of 16.8%. Operative risk is increased in the setting of co-morbid conditions including advanced age [24, 25] . Our patients were judged poor candidates for routine surgery with an estimated logistic Euroscore operative mortality of 31 AE 23%. The observed 30-day mortality of 14% is encouraging.
The feasibility of percutaneous valve implantation was first demonstrated in an animal model by Anderson et al. [7] . Subsequently several groups, including our own, pursued the development of percutaneous heart valves [7] [8] [9] [10] [11] [12] [13] . Percutaneous aortic valve implantation in humans was first performed as a transvenous transseptal procedure with antegrade access to the aortic valve by Cribier et al. [14, 15] . However, the technical complexity and associated risks with this procedure appear likely to limit its widespread application.
Authors reported the development of a transarterial retrograde technique with which initial results have been favorable [17, 18] . Evaluation of this procedure is ongoing and remains encouraging. Although the transfemoral arterial procedure has proven successful, some patients are poorly suited to this approach due to femoral, iliac or aortic size, tortuosity, aneurysm, atheroma, or dissection. This has led to the further development of an alterative approach via the left ventricular apex for aortic valve implantation, which is independent of central and/or peripheral arterial size, anatomy, or diseases. Our initial percutaneous valve development had utilized direct balloon catheter implantation from the left ventricular apex in a porcine model [12] . Subsequently, we reported the first successful case of aortic valve implantation via a left mini-thoracotomy and the left ventricular apex without CPB in human [19] and our initial experience in this approach [21] .
Valvuloplasty data suggests that stroke is a surprisingly infrequent occurrence despite heavy aortic valve calcification [6, 23] . It is likely that the calcific debris familiar to surgeons replacing the aortic valve results from violation of the aortic valve endothelium when resecting the valve. If this covering is kept intact during valvuloplasty and valve deployment, embolization does not occur despite displacement or even crumbling of the calcium within this covering. Coronary obstruction or stroke could conceivably occur due to embolization of friable valvular debris, although this has not been observed with percutaneous valve implantation [17] . In this initial series of seven patients, aortic valvuloplasty and deployment of the aortic prostheses were not associated with stroke or coronary obstruction. Device embolization was an unpredictable concern during early percutaneous experience. However, with accurate positioning, sizing, and deployment techniques, prosthesis embolization appears to be rare as reflected in this initial apical access experience. Furthermore, the inappropriate positioning of prosthesis may be less frequent using the left ventricular apex approach given the nature of its antegrade approach and very short distance to reach the valve.
The transapical transcatheter approach to aortic valve implantation is safe and reliable with minimal operative risks and good early outcome as reflected in this series. The postoperative recovery, length of hospital stay, and late survival are dependent on preoperative comorbidities. This minimally invasive aortic valve implantation appears to be an acceptable approach to symptomatic aortic stenosis in patients who are deemed to be non-surgical candidates. The procedure provides immediate relief of AS-related symptoms and significantly improves quality of life.
Trivial to mild paravalvular regurgitation appears to be common immediately after successful deployment of prosthesis. However, no worsening of the paravalvular regurgitation was observed during the 6-month follow-up, and in no patient did the residual paravalvular leak appear clinically significant in this series. Significant prosthetic regurgitation was not observed in any patients, and aortic valvular area and transvalvular gradient were stable during 6-month follow-up. In summary, aortic valve implantation is feasible via a minimally invasive apical approach without the need for cardiopulmonary bypass. The early results in the initial series are favorable. This initial experience suggests minimally invasive transapical approach is a new, viable alternative for patients in whom open-heart surgery is not feasible or poses unacceptable risks.
